Catalyst Wire Dossier Catalyst Wire Dossier

CD38 CAR-T cell immunotherapy

CD38 CAR-T
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD38 CAR-T cell immunotherapy, covering 2018-12-07 to 2018-12-07. Get the full timeline:

Most recent: Clinical Trial Update: A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy [Phase 1, Phase 2]

See pricing